Rank #1614SUPN

Supernus Pharmaceuticals, Inc.

$51.35

2.29% (Daily)

Market Cap

$2.94B

Revenue

$681.54M

Rank by MCap

#1614

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Jack A. Khattar M.B.A.

Headquarters

Rockville, MD

Employees

674

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy tre...